WRNMMC UsTOO! Chapter
The WRAMC chapter of Us TOO International (now called the WRNMMC chapter), in partnership with CPDR since Aug 1991, provides education and support to military and civilian men with prostate cancer and their families through its popular monthly support group meetings. The Patient Educator and a prostate cancer survivor co-facilitate two meetings each month (a daytime and an evening group) offering approximately 25-30 patients and their families the opportunity to share with others their cancer story and to learn more about prostate cancer, various treatment modalities and issues related to post-treatment, as well as clinical research opportunities.
The WRNMMC UsTOO! chapter also hosts a quarterly Guest Speaker Program for the military and civilian community of prostate cancer patients and their families. An invited health care professional speaks to the group on important issues for men with prostate cancer. This quarterly event typically draws about 30-60 attendees. The presentations, as well as other pertinent items of interest, are published in the WRNMMC Us TOO quarterly newsletter. The newsletter is mailed to its readership of approximately 2200 men. In August 2011, as Walter Reed Army Medical Center closed and moved to Walter Reed National Military Medical Center, the newsletter became an online publication only available on the CPDR website.
To facilitate continuity of care for our prostate cancer patients (particularly during the moves to WRNMMC and Fort Belvoir Community Hospital), the CPDR e-News was expanded to a wider population of CPDR patients. The CPDR e-News is a monthly email message sent to currently 1300 patients providing updated information regarding CPDR, support groups, educational presentations and resources, and research opportunities as appropriate as well as the quarterly Us TOO newsletter.
For information about the monthly support groups at Walter Reed National Military Medical Center and Fort Belvoir Community Hospital, please contact Dr. Jane Hudak (phone: 301-319-2900)
September 29, 2014
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).
Read Full Article.
Read Publication - European Urology
Read the NOVEMEBR 2014 Newsletter